More than 150 coronavirus vaccines are in development across the world but now one of the world's largest pharmaceutical companies and largest conglomerates in terms of revenue, US drugmaker Pfizer has reportedly prepared a vaccine in collaboration with German partner BioNTech to battle the novel coronavirus and it has proven 90% effectiveness in terms of preventing COVID-19 spread.
Moreover, the vaccine has given positive results and is in phase 3 of the trial. The protection in patients was achieved seven days after the second of two doses, and 28 days after the first, according to preliminary findings. Is this a new world order? A freaking vaccine that could prevent the spreading of the novel coronavirus up to 90% in real?
Pfizer is a multinational pharmaceutical corporation headquartered in New York City. In 2012, it was one of the world's largest pharmaceutical companies and ranked 57 on the 2018 Fortune 500 list of the largest United States corporations by total revenue.
The company develops and produces medicines and vaccines for a wide range of medical disciplines, including immunology, oncology, cardiology, endocrinology, and neurology. Its products include the blockbuster drug Lipitor (atorvastatin), used to lower LDL blood cholesterol; Lyrica (pregabalin) for neuropathic pain and fibromyalgia; Diflucan (fluconazole), an oral antifungal medication; Zithromax (azithromycin), an antibiotic; Viagra (sildenafil) for erectile dysfunction; and Celebrex (also Celebra, celecoxib), an anti-inflammatory drug.
In 2016, Pfizer Inc. was expected to merge with Allergan to create the Ireland-based "Pfizer plc" in a deal that would have been worth US$160 billion. The merger was called off in April 2016, however, because of new rules from the US Department of the Treasury against tax inversions, a method of avoiding taxes by merging with a foreign company.
The company has made the second-largest pharmaceutical settlement with the United States Department of Justice. On December 19, 2018, Pfizer announced a joint merger of their consumer healthcare division with UK pharma giant GlaxoSmithKline; the British company will maintain a controlling 68% of shares.
Pfizer was a constituent of the Dow Jones Industrial Average from 2004 to 2020, when it was announced that the company would be replaced by Amgen in the Dow Jones. The change took effect at the start of trading on August 31, 2020.
Pfizer is repeatedly successful in being able to offer effective medicines in the fight against and alleviation of diseases.